Dr Jim Coward

A/Prof Jim Coward

Become a Patient

I aim to deliver a comprehensive oncology service by incorporating scientific research from the laboratory into cancer care and provide direct access to state-of-the-art clinical trials.


A/Prof Jim Coward is a medical oncologist and Associate Professor of Medicine at UQ School of Medicine and Mater Research, TRI. He is based at Icon Cancer Centre South Brisbane and Chermside, and has a strong focus on the holistic care of patients with a wide variety of malignancies, in particular gynaecological, head and neck, gastrointestinal and lung cancers.

Completing his medical training at Imperial College, London in 1998, A/Prof Coward became a member of the Royal College of Physicians in 2002. His interest in the field of oncology began during his tenure as a junior doctor and he subsequently undertook specialist registrar training at Westmead Hospital, Sydney and the world renowned Royal Marsden Hospital, London.

In 2006, A/Prof Coward was appointed as a MRC clinical fellow at the Barts Cancer Institute, London, where his research on the effects of immunotherapy in advanced ovarian cancer successfully translated into a clinical trial in patients with platinum resistant disease. This work culminated in a PhD award from Queen Mary, University London in 2010, cementing A/Prof Coward’s desire to dedicate his career to cancer research. He has over 30 peer-reviewed publications and book chapters with numerous citations in leading scientific and clinical journals. Alongside his continuing supervision of clinical trainees and PhD students, A/Prof Coward is a regular lecturer at national conferences.

A/Prof Coward is actively involved in a number of high calibre international research collaborations with clinicians and scientists within prominent international cancer institutes. In addition, as a passionate advocate of gynaecological cancer research, A/Prof Coward speaks at charity events and public forums educating patients and their relatives about his research, and proactively seeks to increase public awareness about ovarian cancer.

For further detail, please visit cowardoncology.com.au

Clinical Trials

A/Prof Coward is heavily invested in providing cutting edge medicines through a rapidly evolving phase one research portfolio. Supported by Icon Cancer Foundation, he has a predominant focus on immunotherapy based clinical trials for all solid tumour types.

Special Interests

A/Prof Jim Coward accepts referrals for all cancer types, with a special clinical interest in:
  • Breast cancer
  • Gastrointestinal cancer
  • Gynaecological cancer
  • Head and neck cancer
  • Lung cancer


  • Rethinking ovarian cancer There have been major advances in our understanding of the cellular and molecular biology of the human malignancies that are collectively referred to as ovarian cancer. At a recent Helene Harris Memorial Trust meeting, an international group of researchers considered actions that should be taken to improve the outcome for women with ovarian cancer. Nine major recommendations are outlined in this Opinion article. https://cowardoncology.com.au/2018/01/21/rethinking-ovarian-cancer/

  • IL-6 in gynaecological cancers This article provides an overview on IL-6 biology including updates on novel discoveries in IL-6 signalling and then focuses on the role of IL-6 in processes such as cell proliferation, migration, angiogenesis, evasion of tumour immunity and chemoresistance and presents data relating to the abrogation of these processes with anti-IL-6 targeted therapy in preclinical and clinical studies https://cowardoncology.com.au/2018/01/21/il-6-in-gynaecological-cancers/

  • Chemotherapy advances in small-cell lung cancer This review is introduced with an overview on the historical development of chemotherapeutic regimens used in this disease and followed by the recent encouraging advances witnessed in clinical trials with drugs such as amrubicin and belotecan which are forging new horizons for future treatment algorithms. https://cowardoncology.com.au/2018/01/21/chemotherapy-advances-in-small-cell-lung-cancer/

  • New perspectives on targeted therapies in ovarian cancer This review summarizes the key studies with antiangiogenic agents, poly(adenosine diphosphate [ADP]-ribose) inhibitors, and epidermal growth factor receptor/human epidermal growth factor receptor family targeting, in addition to folate receptor antagonists and insulin growth factor receptor inhibitors. The efficacy of treatment paradigms used in non-ovarian malignancies for type I tumors is also highlighted, in addition to recent advances in appropriate patient stratification for targeted therapies in epithelial ovarian cancer. https://cowardoncology.com.au/2017/10/14/new-perspectives/

  • Inflammation and ovarian cancer Constitutive production of inflammatory cytokines is a characteristic of many human malignant cell lines; however, the in vitro and in vivo interdependence of these cytokines, and their significance to the human cancer microenvironment, are both poorly understood. Here, we describe for the first time how three key cytokine / chemokine mediators of cancer-related inflammation, TNF, CXCL12, and interleukin 6, are involved in an autocrine cytokine network, the “TNF network,” in human ovarian cancer. https://cowardoncology.com.au/2018/01/21/inflammation-and-ovarian-cancer/

  • For a full list of published articles and active clinical trials please visit cowardoncology.com.au